Jaime Espín

1.3k total citations
69 papers, 794 citations indexed

About

Jaime Espín is a scholar working on Economics and Econometrics, General Health Professions and Immunology. According to data from OpenAlex, Jaime Espín has authored 69 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Economics and Econometrics, 15 papers in General Health Professions and 10 papers in Immunology. Recurrent topics in Jaime Espín's work include Health Systems, Economic Evaluations, Quality of Life (43 papers), Pharmaceutical Economics and Policy (36 papers) and Innovation Policy and R&D (8 papers). Jaime Espín is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (43 papers), Pharmaceutical Economics and Policy (36 papers) and Innovation Policy and R&D (8 papers). Jaime Espín collaborates with scholars based in Spain, United Kingdom and Italy. Jaime Espín's co-authors include David Epstein, Emilio Sánchez‐Cantalejo, Esther Molina‐Montes, Joan Rovira, María‐José Sánchez, Leticia García‐Mochón, Sabine Vogler, Claudia Habl, Antonio Olry de Labry Lima and Juan Carlos Rejón-Parrilla and has published in prestigious journals such as SHILAP Revista de lepidopterología, Social Science & Medicine and BMC Public Health.

In The Last Decade

Jaime Espín

62 papers receiving 768 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaime Espín Spain 17 411 112 107 101 93 69 794
Chris Skedgel Canada 21 319 0.8× 128 1.1× 101 0.9× 198 2.0× 54 0.6× 76 1.3k
Amr Makady Netherlands 12 643 1.6× 171 1.5× 82 0.8× 92 0.9× 86 0.9× 27 1.2k
Ateesha F. Mohamed United States 23 540 1.3× 194 1.7× 77 0.7× 200 2.0× 77 0.8× 66 1.3k
Mattias Neyt Belgium 19 343 0.8× 108 1.0× 187 1.7× 221 2.2× 101 1.1× 103 1.2k
James D. Chambers United States 22 671 1.6× 205 1.8× 47 0.4× 118 1.2× 148 1.6× 90 1.2k
Joshua Cohen United States 18 399 1.0× 99 0.9× 71 0.7× 37 0.4× 105 1.1× 59 824
Louis Dron Canada 15 192 0.5× 79 0.7× 106 1.0× 103 1.0× 72 0.8× 35 1.2k
Diana Brixner United States 10 461 1.1× 194 1.7× 58 0.5× 96 1.0× 65 0.7× 37 977
Virginie Nerich France 20 208 0.5× 94 0.8× 221 2.1× 334 3.3× 75 0.8× 83 1.2k
Sang Mee Lee United States 16 119 0.3× 244 2.2× 84 0.8× 157 1.6× 113 1.2× 50 880

Countries citing papers authored by Jaime Espín

Since Specialization
Citations

This map shows the geographic impact of Jaime Espín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaime Espín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaime Espín more than expected).

Fields of papers citing papers by Jaime Espín

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaime Espín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaime Espín. The network helps show where Jaime Espín may publish in the future.

Co-authorship network of co-authors of Jaime Espín

This figure shows the co-authorship network connecting the top 25 collaborators of Jaime Espín. A scholar is included among the top collaborators of Jaime Espín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaime Espín. Jaime Espín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Espín, Jaime, et al.. (2024). Cost-Minimization Analysis of Tolvaptan Treatment for ADPKD in Southern Spain. Kidney International Reports. 10(1). 265–266. 1 indexed citations
2.
Espín, Jaime, et al.. (2024). Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature. Value in Health Regional Issues. 42. 100981–100981. 1 indexed citations
3.
Vogler, Sabine, Nina Zimmermann, Maximilian Salcher‐Konrad, et al.. (2024). ‘We need to be part of the solution’: lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies. Journal of Pharmaceutical Policy and Practice. 17(sup1). 2442002–2442002. 2 indexed citations
4.
Drummond, Michael, Oriana Ciani, Claudio Jommi, et al.. (2023). How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?. BMC Health Services Research. 23(1). 484–484. 22 indexed citations
5.
Sequera, Patricia de, et al.. (2023). Impact of pruriture associated with chronic renal disease (PaCKD) on the quality of life of patients in hemodialysis in Spain. Nefrología (English Edition). 43(6). 663–667.
6.
Rejón-Parrilla, Juan Carlos, et al.. (2023). Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Frontiers in Pharmacology. 14. 1199500–1199500. 8 indexed citations
7.
Pingret, Daniella, et al.. (2022). Medicines pricing and reimbursement: innovation, competitiveness, and access. SHILAP Revista de lepidopterología. 13(1). 679–679. 4 indexed citations
8.
Stamuli, Eugena, et al.. (2022). Patient Preferences for Breast Cancer Treatments: A Discrete Choice Experiment in France, Ireland, Poland and Spain. Future Oncology. 18(9). 1115–1132. 11 indexed citations
9.
Facey, Karen, Jaime Espín, E. Kent, et al.. (2021). Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. PharmacoEconomics. 39(9). 1021–1044. 35 indexed citations
10.
Kent, Seamus, Maximilian Salcher‐Konrad, Stefania Boccia, et al.. (2021). The use of nonrandomized evidence to estimate treatment effects in health technology assessment. Journal of Comparative Effectiveness Research. 10(14). 1035–1043. 17 indexed citations
11.
Espín, Jaime, et al.. (2021). Towards a taxonomy of judicialisation for access to medicines in Latin America. Global Public Health. 17(6). 912–925. 2 indexed citations
12.
García‐Mochón, Leticia, Joan Forns, & Jaime Espín. (2021). Cost transferability problems in economic evaluation as a framework for an European health care and social costs database. Cost Effectiveness and Resource Allocation. 19(1). 43–43. 11 indexed citations
13.
Kaló, Zoltán, et al.. (2021). Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. Cost Effectiveness and Resource Allocation. 19(1). 42–42. 6 indexed citations
14.
Calleja, Miguel Ángel, Olga Delgado Sánchez, Jaime Espín, et al.. (2021). A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study). Orphanet Journal of Rare Diseases. 16(1). 186–186. 13 indexed citations
15.
Cardoso, Fátima, Nils Wilking, Renato Bernardini, et al.. (2020). A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments. The Breast. 52. 78–87. 9 indexed citations
16.
Angelis, Aris, Mark Linch, Gilberto Montibeller, et al.. (2019). Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. Social Science & Medicine. 246. 112595–112595. 28 indexed citations
17.
Tordrup, David, C. Chouaïd, Pim Cuijpers, et al.. (2017). PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. International Journal of Technology Assessment in Health Care. 33(6). 609–619. 6 indexed citations
18.
Molina‐Montes, Esther, Mar Requena, Emilio Sánchez‐Cantalejo, et al.. (2014). Risk of second cancers cancer after a first primary breast cancer: A systematic review and meta-analysis. Gynecologic Oncology. 136(1). 158–171. 82 indexed citations
19.
20.
Rovira, Joan, et al.. (2011). PHP30 Biosimilars in the European Market. Value in Health. 14(7). A338–A338. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chris Skedgel Breakdown of academic impact, for papers by Amr Makady Breakdown of academic impact, for papers by Ateesha F. Mohamed Breakdown of academic impact, for papers by Mattias Neyt Breakdown of academic impact, for papers by James D. Chambers Breakdown of academic impact, for papers by Joshua Cohen Breakdown of academic impact, for papers by Louis Dron Breakdown of academic impact, for papers by Diana Brixner Breakdown of academic impact, for papers by Virginie Nerich Breakdown of academic impact, for papers by Sang Mee Lee
Rankless by CCL
2026